Publikationen (251) Publikationen, an denen Forscher/innen teilgenommen haben

2024

  1. A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833

  2. An in vitro analysis of the interaction between infliximab and granulocyte–monocyte apheresis

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 347-351

  3. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 246-252

  4. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  5. Combination of granulocyte–monocyte apheresis and tofacitinib: Multicentre and retrospective study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 727-733

  6. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  7. Early Biological Therapy Within 12 Months of Diagnosis Leads to Higher Transmural Healing Rates in Crohn's Disease

    Clinical Gastroenterology and Hepatology

  8. Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis

    Alimentary Pharmacology and Therapeutics

  9. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  10. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials

    United European Gastroenterology Journal, Vol. 12, Núm. 7, pp. 960-981

  11. Efficacy of Beclomethasone Dipropionate in Lowering Fecal Calprotectin Levels in Patients with Ulcerative Colitis in Clinical Remission and at Risk of Relapse: The Becalcu Randomized, Controlled Trial

    Digestive Diseases

  12. Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease

    Crohn's and Colitis 360, Vol. 6, Núm. 1

  13. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  14. Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758

  15. Magnetic Resonance Imaging Features Indicative of Permanent Colon Damage in Ulcerative Colitis: An Exploratory Study

    Journal of Crohn's and Colitis, Vol. 18, Núm. 10, pp. 1690-1700

  16. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  17. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

  18. Prophylactic versus endoscopy-driven treatment of crohn's postoperative recurrence: A retrospective, multicentric, european study [porcse study]

    Journal of Crohn's and Colitis, Vol. 18, Núm. 8, pp. 1202-1214

  19. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study

    Journal of Clinical Medicine, Vol. 13, Núm. 2

  20. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476